Canagliflozin 100 mg (Generic)

Product Overview

Canagliflozin 100 mg (Generic) is a prescription oral medication indicated for the management of type 2 diabetes mellitus. Manufactured by Wallace Pharmaceuticals Pvt. Ltd., this product is supplied in packs of 10 tablets per strip, with available pack sizes of 50, 100, and 200 tablets. The active ingredient, canagliflozin, belongs to the sodium‑glucose cotransporter‑2 (SGLT‑2) inhibitor class and works by reducing renal glucose reabsorption, thereby lowering blood glucose levels. The medication is intended for daily oral use as part of a comprehensive diabetes care plan that includes diet, exercise, and regular monitoring of blood sugar. Information is consistent with guidance from the National Institutes of Health and the U.S. Food and Drug Administration.

What is Canagliflozin 100 mg (Generic)

Canagliflozin is a synthetic compound that inhibits the SGLT‑2 transporter in the proximal renal tubule. By blocking this transporter, the drug promotes the excretion of excess glucose through urine, which helps achieve better glycemic control in adults with type 2 diabetes. The generic formulation offers the same therapeutic efficacy as the branded version while providing a cost‑effective option for patients and healthcare providers. This mechanism is described in detail by research published in peer‑reviewed journals indexed on PubMed.

Uses and Benefits

The primary use of canagliflozin 100 mg is to improve glycemic control in adults with type 2 diabetes when diet and exercise alone are insufficient. Clinical studies have demonstrated that treatment can lead to modest reductions in HbA1c, body weight, and systolic blood pressure, contributing to cardiovascular risk reduction. In addition, the medication has been shown to lower the risk of hospitalization for heart failure and to slow the progression of diabetic nephropathy in patients with existing kidney disease. These benefits make canagliflozin a valuable component of a multimodal approach to diabetes management, supporting both metabolic control and long‑term health outcomes.

How It Works

Canagliflozin acts on the SGLT‑2 protein located in the first segment of the nephron. Under normal physiological conditions, SGLT‑2 reabsorbs filtered glucose back into the bloodstream. Inhibition of this protein prevents glucose reabsorption, resulting in increased urinary glucose excretion. This mechanism does not rely on insulin signaling, which distinguishes SGLT‑2 inhibitors from many other antidiabetic agents. The resulting caloric loss contributes to weight loss, while the reduction in plasma glucose helps lower the risk of hyperglycemic complications. Further details can be found on the MedlinePlus consumer page.

Dosage Guidelines

Canagliflozin 100 mg is typically administered once daily, at the same time each day, with or without food. The recommended starting dose for most adults with type 2 diabetes is 100 mg, which may be titrated up to 300 mg based on glycemic response and tolerability, under the supervision of a healthcare professional. Patients with impaired renal function should consult their physician before initiating therapy, as dose adjustments are recommended when the estimated glomerular filtration rate (eGFR) falls below 60 mL/min/1.73 m². It is essential to follow the prescribing clinician’s instructions regarding dosage and to avoid self‑adjustment. Routine monitoring of kidney function is advised to ensure safe use.

Side Effects

Like all medications, canagliflozin may cause adverse effects. The most commonly reported side effects include increased urinary frequency, genital mycotic infections, and urinary tract infections. Some patients may experience dehydration, dizziness, or orthostatic hypotension, particularly if fluid intake is inadequate. Rare but serious complications can include diabetic ketoacidosis, especially in situations of reduced carbohydrate intake, surgery, or acute illness. Patients should be advised to monitor for signs of infection, maintain adequate hydration, and seek medical attention if they develop severe abdominal pain, nausea, or unexplained fatigue. Reporting of adverse events to a healthcare provider is encouraged.

Warnings and Precautions

Canagliflozin is not indicated for the treatment of type 1 diabetes or for patients with a history of diabetic ketoacidosis. The drug should be used with caution in patients with a prior history of kidney disease, liver disease, or pancreatitis. Concomitant use with insulin or sulfonylureas may increase the risk of hypoglycemia; dose adjustments may be necessary. Patients should be advised to inform their healthcare provider of any new medications, supplements, or changes in kidney function. Routine laboratory monitoring, including eGFR and serum ketones when clinically indicated, is recommended to ensure safe use. Additional safety information is available from the U.S. Food and Drug Administration drug label.

Frequently Asked Questions

Can I take canagliflozin if I have type 1 diabetes?

No, canagliflozin is not approved for type 1 diabetes and should not be used in that population.

Do I need to monitor my kidney function while taking this medication?

Yes, regular assessment of estimated glomerular filtration rate (eGFR) is recommended to ensure the drug is appropriate for your renal health.

What should I do if I miss a dose of canagliflozin?

Take the missed dose as soon as you remember, unless it is almost time for the next scheduled dose; do not double the dose to catch up.

Can I use this medication during pregnancy or while breastfeeding?

It is not recommended for use during pregnancy or breastfeeding; discuss alternative treatment options with your healthcare provider.

Will I experience weight loss while taking canagliflozin?

Many patients notice modest weight loss due to the caloric excretion that occurs through increased urine glucose, though individual results may vary.